Divi’s Laboratories (DIVISLAB) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
7 Nov, 2026Executive summary
Q2 FY27 consolidated total income rose 32% YoY to ₹3,770 crore; PBT increased 65% to ₹1,505 crore and PAT increased 64% to ₹1,127 crore.
H1 FY27 consolidated total income was ₹6,907 crore, PBT ₹2,685 crore and PAT ₹2,029 crore, versus ₹5,389 crore, ₹1,645 crore and ₹1,234 crore, respectively, a year earlier.
Financial highlights
Consolidated Q2 FY27 revenue from operations was ₹3,676 crore versus ₹2,715 crore in Q2 FY26; H1 revenue was ₹6,756 crore versus ₹5,125 crore.
Standalone H1 revenue grew 17% YoY on a constant-currency basis; exports were ~90% of standalone sales, with Europe and North America contributing ~75%.
H1 nutraceutical revenue was ₹571 crore versus ₹492 crore YoY.
H1 consolidated forex gain was ₹17 crore versus ₹102 crore; at Sep. 30, 2026, cash was ₹2,181 crore, receivables ₹3,705 crore and inventories ₹5,325 crore.
Consolidated EPS was ₹42.49 in Q2 FY27 and ₹76.44 in H1 FY27, versus ₹25.97 and ₹46.46 in the prior-year periods; figures are not annualized.
Outlook and guidance
Revenue growth guidance remains double-digit; management gave no narrower H2 range and did not raise its prior EBITDA margin guidance.
Annual CapEx outlook is ~₹2,000 crore, +/-20%, over the next two to three years, based on RFPs and customer opportunities.
Three major dedicated projects are progressing through qualification; one is near commercialization and two are expected to commercialize over the next few quarters, subject to approvals.
No capacity shortage is currently expected; capacity additions are planned with customers and in response to opportunities.
Latest events from Divi’s Laboratories
- PAT rose 39.16% as expansion plans advanced and R&D write-offs weighed on reported profit.DIVISLAB
Q4 01/02 - Sales and PAT grew strongly as Chippada launched and exports drove 91% of turnover.DIVISLAB
Q4 02/03 - Sales grew 15%, but higher costs and taxes reduced FY05 earnings.DIVISLAB
Q4 04/05 - FY04 sales and PAT grew strongly as exports and API capacity expanded.DIVISLAB
Q4 03/04 - Export-led growth drove 90% sales growth as major capacity expansion came online.DIVISLAB
Q4 06/07 - Sales and PAT grew as exports and capacity expansion drove the FY07 growth agenda.DIVISLAB
Q4 05/06 - FY08 sales rose 43% and PAT 84% as capacity expanded and exports dominated.DIVISLAB
Q4 07/08 - FY09 growth persisted, but FX losses, destocking and disputed SEZ tax clouded results.DIVISLAB
Q4 08/09 - Destocking cut FY10 sales 22%; capacity expansion targets the recovery.DIVISLAB
Q4 09/10